G005711

LC/MS Analysis of Omeprazole and Metabolites in Plasma on Ascentis^® Express RP Amide after Sample Prep using HybridSPE^®-Phospholipid

application for HPLC, application for SPE

Eigenschaften

• Methode(n): HPLC: suitable; solid phase extraction (SPE): suitable
• Testparameter: sample preparation: SPE (Solid Phase Extraction); sample/matrix: rat plasma spiked with omeprazole, phenacetin and metabolites at 2 μg/mL; SPE well plate: HybridSPE-Phospholipid, 96-well plate, 15 mg/0.8 mL (575656-U); sample addition: 100 μL plasma to each well, followed by 300 mL of 1% formic acid in acetonitrile; elution: apply vacuum; eluate post-treatment: eluate was collected, evaporated, and reconstituted in mobile phase.; column: Ascentis Express RP-Amide, 5 cm x 2.1 mm I.D., 2.7 μm particles (53911-U); mobile phase: [A] water, 10 mM ammonium formate, pH 3.4; [B] methanol, 10 mM ammonium formate, pH 3.4; (65:35, A:B); flow rate: 0.3 mL/min; column temp.: 35 °C; detector: ESI(+), m/z = 50-400; injection: 1 μL
• Eignung: application for HPLC; application for SPE
• Anwendung(en): clinical

Beschreibung

Anwendung

This application demonstrates the suitability of HybridSPE and the Ascentis Express RP Amide for the analysis of omeprazole metabolites.

Hinweis zur Analyse

Sample was vorlexed and centrifuged for 2 minutes at 15000 rpm. Supemate was then passed through HybridSPE 96 well plate. Elutent was collected, evaporated and reconstituted in mobile phase.

Rechtliche Hinweise

Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany

HybridSPE is a registered trademark of Merck KGaA, Darmstadt, Germany

Analyt

5-Hydroxyomeprazole
Phenacetin
Omeprazole
Omeprazole sulfone